Literature DB >> 29286232

Development of Cationic Quaternary Ammonium Sulfonamide Amino Lipids for Nucleic Acid Delivery.

Jason B Miller1, Petra Kos1, Victor Tieu1, Kejin Zhou1, Daniel J Siegwart1.   

Abstract

Lipid nanoparticles (LNPs) currently comprise the most effective carrier class for the delivery of small RNAs. Among lipid carriers, charge-unbalanced lipids are relatively unexplored synthetically. Herein, we developed and evaluated a novel collection of compounds for small interfering RNA (siRNA) delivery, termed cationic quaternary ammonium sulfonamide amino lipids (CSALs). The formulated CSAL LNPs containing cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine, and lipid poly(ethylene glycol) exhibited biophysical property trends directly related to the CSAL chemical structure. Lead CSAL LNPs were identified using an siRNA delivery screen. Further chemical synthesis using a rational structure-guided design showed that the head group structure could alter the pKa and other physical properties that modulated delivery efficacy. Shorter-chained dimethylamino head groups, acetate side chains, and higher tail carbon numbers were favorable for delivery. This led to a further study of A3-OAc-C2Me LNPs, which enabled in vivo delivery to normal mouse lungs and subcutaneous and orthotopic lung tumors. Incorporation of CSALs into liver-targeting formulations shifted the in vivo delivery of these carriers to the lungs. This study highlights the importance of the cationic lipid structure in LNPs and provides further design guidelines for nucleic acid carriers.

Entities:  

Keywords:  cancer; lipid nanoparticles; lipid synthesis; lung delivery; siRNA

Mesh:

Substances:

Year:  2018        PMID: 29286232     DOI: 10.1021/acsami.7b15982

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  5 in total

1.  The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs.

Authors:  Samuel T LoPresti; Mariah L Arral; Namit Chaudhary; Kathryn A Whitehead
Journal:  J Control Release       Date:  2022-03-26       Impact factor: 11.467

2.  Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for In Vivo CRISPR/Cas-Based Genome Editing.

Authors:  Tuo Wei; Qiang Cheng; Lukas Farbiak; Daniel G Anderson; Robert Langer; Daniel J Siegwart
Journal:  ACS Nano       Date:  2020-07-22       Impact factor: 15.881

3.  Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR-Cas gene editing.

Authors:  Shuai Liu; Qiang Cheng; Tuo Wei; Xueliang Yu; Lindsay T Johnson; Lukas Farbiak; Daniel J Siegwart
Journal:  Nat Mater       Date:  2021-02-04       Impact factor: 47.656

Review 4.  Therapeutic RNA Delivery for COVID and Other Diseases.

Authors:  Curtis Dobrowolski; Kalina Paunovska; Marine Z C Hatit; Melissa P Lokugamage; James E Dahlman
Journal:  Adv Healthc Mater       Date:  2021-03-04       Impact factor: 11.092

5.  Genome-editing prodrug: Targeted delivery and conditional stabilization of CRISPR-Cas9 for precision therapy of inflammatory disease.

Authors:  Xiaojie Yan; Qi Pan; Huhu Xin; Yuxuan Chen; Yuan Ping
Journal:  Sci Adv       Date:  2021-12-08       Impact factor: 14.136

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.